Surgical decisions made by 158 women with hereditary breast cancer aged <50 years

被引:35
作者
Evans, DGR
Lalloo, F
Hopwood, P
Maurice, A
Baildam, A
Brain, A
Barr, L
Howell, A
机构
[1] St Marys Hosp, Acad Unit Med Genet, Manchester M13 0JH, Lancs, England
[2] St Marys Hosp, Reg Genet Serv, Manchester M13 0JH, Lancs, England
[3] S Manchester Univ Hosp Trust, Withington Hosp, Nightingale Ctr, Breast Canc Family Hist Clin, Manchester, Lancs, England
[4] Christie Hosp, Dept Psychol Med, Manchester M20 9BX, Lancs, England
[5] Christie Hosp, Dept Plast Surg, Manchester M20 9BX, Lancs, England
[6] S Manchester Univ Hosp Trust, Dept Surg, Manchester, Lancs, England
[7] Christie Hosp, Dept Med Oncol, Manchester, Lancs, England
来源
EJSO | 2005年 / 31卷 / 10期
关键词
BRCA1; BRCA2; risk-reducing mastectomy; contralateral;
D O I
10.1016/j.ejso.2005.05.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To establish the uptake of contralateral risk reducing mastectomy in women informed of their risks and options at time of diagnosis of their primary unilateral breast cancer. Methods: We have assessed the surgical choices of 70 women diagnosed with breast cancer <50 years as part of a family history surveillance program and fully informed about their contralateral. risks and surgical options. We have compared this to women from other surgical clinics who were subsequently found to harbour a pathogenic BRCA1/2 mutation. Results: Sixty-five percent (13/20) of BRCA1/2 mutation carriers and 59% (n=20/34) of those at the highest level of risk pre-diagnosis (33+% lifetime risk) opted for contra-lateral mastectomy in the study sample. In contrast only 10% (n=9/88) women identified as mutation carriers from other clinics opted for such surgery. Conclusions: We would suggest that women with a significant family history and therefore a high contra-lateral breast cancer risk, should have these risks and management options discussed at the time of diagnosis of breast cancer. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1112 / 1118
页数:7
相关论文
共 33 条
[1]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[2]  
Baum M, 2003, Cancer, V98, P1802
[3]   Changes in psychological distress after cancer genetic counselling: a comparison of affected and unaffected women [J].
Bish, A ;
Sutton, S ;
Jacobs, C ;
Levene, S ;
Ramirez, A ;
Hodgson, S .
BRITISH JOURNAL OF CANCER, 2002, 86 (01) :43-50
[4]  
CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO
[5]  
2-5
[6]   Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation [J].
Contant, CME ;
Menke-Pluijmers, MBE ;
Seynaeve, C ;
Meijers-Heijboer, EJ ;
Klijn, JGM ;
Verhoog, LC ;
Wai, RTJ ;
Eggermont, AMM ;
van Geel, AN .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (06) :627-632
[7]   Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility:: Findings from p53 and BRCA1 testing programs [J].
Dorval, M ;
Patenaude, AF ;
Schneider, KA ;
Kieffer, SA ;
DiGianni, L ;
Kalkbrenner, KJ ;
Bromberg, JI ;
Basili, LA ;
Calzone, K ;
Stopfer, J ;
Weber, BL ;
Garber, JE .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) :2135-2142
[8]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[9]   Familial breast cancer: An investigation into the outcome of treatment for early stage disease [J].
Eccles D. ;
Simmonds P. ;
Goddard J. ;
Coultas M. ;
Hodgson S. ;
Lalloo F. ;
Evans G. ;
Haites N. .
Familial Cancer, 2001, 1 (2) :65-72
[10]   The pathology of familial breast cancer:: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 [J].
Lakhani, SR ;
van de Vijver, MJ ;
Jacquemier, J ;
Anderson, TJ ;
Osin, PP ;
McGuffog, L ;
Easton, DF .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2310-2318